

Our Reference: BLA 125611/0

Novo Nordisk Inc.  
Attention: Ms. Patricia D. Wilson  
March 27, 2017  
Sent by email

Dear Ms. Wilson:

We are reviewing your May 16, 2016 biologics license application for Coagulation Factor IX (Recombinant), GlycoPEGylated. We are providing the following comments and request for additional information to continue our review:

Please reference your response submitted on January 31, 2017 and March 3, 2017, that have been designated as amendments 34 and 40, respectively:

1. In the response to the question 4 of our IR dated Jan. 17, 2017, you provided accuracy data for components of rFIX, (b) (4). This assay is used as PEG profile method for the determination of %Mono-PEG rFIX, in addition to the product related impurities mentioned above, please provide the accuracy data for mono-PEG rFIX.
2. We do not agree with scaling down approach of LOQ determination for %rFIX (b) (4), %rFIX and (b) (4) PEG rFIX in your response for our Q6 because (b) (4) does not change linearly with concentration or amount injected. Please provide appropriate results of evaluation of LOQ of the three above-mentioned impurities. We suggest you calculate the LOQ by plotting impurity peak area against %impurity from corresponding accuracy data for Q4 and using the formula of (b) (4), where  $\sigma$  stands for the standard deviation of the peak area and S for the slope of the linear regression.

The review of this application is on-going and issues may be added, expanded upon, or modified.

Please submit your response for this request as an amendment to this file by April 10, 2017, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is June 3, 2017.

Please send an acknowledgement message for receipt of this request.

If you have any questions, please contact me at (240) 402-8443.

Sincerely,  
Edward Thompson  
Regulatory Project Manager  
FDA/CBER/OTAT/DRPM